FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2788085443> ?p ?o ?g. }

• W2788085443 endingPage "1088.e1" @default.
• W2788085443 startingPage "1081" @default.
• W2788085443 abstract "Background & AimsReshape Duo is a saline-filled dual, integrated intragastric balloon (IGB) approved by the Food and Drug Administration for weight loss in patients with obesity. In a prospective, randomized trial, obese patients who received the balloon had significantly greater percent excess weight loss (%EWL) compared with patients treated with diet and exercise alone. However, there are limited data on the real-world efficacy of the Reshape balloon.MethodsWe performed a retrospective study of data collected from 2 academic centers and 5 private practices in which all patients paid for the IGB and follow-up visits out of pocket. The IGB was removed after 6 months. We collected data (demographic, medical, and laboratory) from 202 adults (mean age 47.8 ± 10.8 years; 83% female) with a baseline mean body mass index of 36.8 + 8.4 kg/m2 who had IGB insertion for weight loss therapy, along with counselling on lifestyle modifications focused on diet and exercise. Primary outcomes were percent total body weight loss (%TBWL) and %EWL at 1, 3, 6, 9, and 12 months after the procedure.ResultsMean %TBWL at 1, 3, 6, 9 and 12 months was 4.8 ± 2.4%, 8.8 ± 4.3%, 11.4 ± 6.7%, 13.3 ± 7.8%, and 14.7 ± 11.8%, respectively. Data were available from 101 patients at 6 months and 12 patients at 12 months; 60.4% of patients achieved more than 10% TBWL and 55.4% had more than 25% EWL. Seventeen patients (8.4%) had esophageal tears during balloon insertion, with no intervention required. Thirteen patients (6.4%) had their IGB removed before the end of the 6-month treatment period. Nausea, vomiting, and abdominal pain were the most common adverse effects, occurring in 149 (73.8%), 99 (49%), and 51 (25.2%) patients. In one patient, the IGB migrated distally leading to small intestinal obstruction requiring surgical removal.ConclusionIn a retrospective analysis of real-world patients who received the Reshape Duo IGB, we found it to be a safe and efficacious endoscopic method for producing weight loss, with most patients achieving greater than 10% TBWL at 6 months. Reshape Duo is a saline-filled dual, integrated intragastric balloon (IGB) approved by the Food and Drug Administration for weight loss in patients with obesity. In a prospective, randomized trial, obese patients who received the balloon had significantly greater percent excess weight loss (%EWL) compared with patients treated with diet and exercise alone. However, there are limited data on the real-world efficacy of the Reshape balloon. We performed a retrospective study of data collected from 2 academic centers and 5 private practices in which all patients paid for the IGB and follow-up visits out of pocket. The IGB was removed after 6 months. We collected data (demographic, medical, and laboratory) from 202 adults (mean age 47.8 ± 10.8 years; 83% female) with a baseline mean body mass index of 36.8 + 8.4 kg/m2 who had IGB insertion for weight loss therapy, along with counselling on lifestyle modifications focused on diet and exercise. Primary outcomes were percent total body weight loss (%TBWL) and %EWL at 1, 3, 6, 9, and 12 months after the procedure. Mean %TBWL at 1, 3, 6, 9 and 12 months was 4.8 ± 2.4%, 8.8 ± 4.3%, 11.4 ± 6.7%, 13.3 ± 7.8%, and 14.7 ± 11.8%, respectively. Data were available from 101 patients at 6 months and 12 patients at 12 months; 60.4% of patients achieved more than 10% TBWL and 55.4% had more than 25% EWL. Seventeen patients (8.4%) had esophageal tears during balloon insertion, with no intervention required. Thirteen patients (6.4%) had their IGB removed before the end of the 6-month treatment period. Nausea, vomiting, and abdominal pain were the most common adverse effects, occurring in 149 (73.8%), 99 (49%), and 51 (25.2%) patients. In one patient, the IGB migrated distally leading to small intestinal obstruction requiring surgical removal. In a retrospective analysis of real-world patients who received the Reshape Duo IGB, we found it to be a safe and efficacious endoscopic method for producing weight loss, with most patients achieving greater than 10% TBWL at 6 months." @default.
• W2788085443 created "2018-03-06" @default.
• W2788085443 creator A5000862541 @default.
• W2788085443 creator A5005545298 @default.
• W2788085443 creator A5009183382 @default.
• W2788085443 creator A5012036209 @default.
• W2788085443 creator A5019673979 @default.
• W2788085443 creator A5027039445 @default.
• W2788085443 creator A5032323138 @default.
• W2788085443 creator A5032847603 @default.
• W2788085443 creator A5034266154 @default.
• W2788085443 creator A5044736668 @default.
• W2788085443 creator A5044808426 @default.
• W2788085443 creator A5055011014 @default.
• W2788085443 creator A5055703254 @default.
• W2788085443 creator A5065695520 @default.
• W2788085443 creator A5065914205 @default.
• W2788085443 creator A5066903532 @default.
• W2788085443 creator A5067749370 @default.
• W2788085443 creator A5069787247 @default.
• W2788085443 creator A5070743956 @default.
• W2788085443 creator A5074626064 @default.
• W2788085443 creator A5075701151 @default.
• W2788085443 creator A5080357947 @default.
• W2788085443 creator A5083810588 @default.
• W2788085443 creator A5087970044 @default.
• W2788085443 creator A5089064008 @default.
• W2788085443 date "2018-07-01" @default.
• W2788085443 modified "2023-09-27" @default.
• W2788085443 title "Real-World Safety and Efficacy of Fluid-Filled Dual Intragastric Balloon for Weight Loss" @default.
• W2788085443 cites W2005863108 @default.
• W2788085443 cites W2006624049 @default.
• W2788085443 cites W2014439798 @default.
• W2788085443 cites W2027524238 @default.
• W2788085443 cites W2067685113 @default.
• W2788085443 cites W2071376205 @default.
• W2788085443 cites W2083402521 @default.
• W2788085443 cites W2093274439 @default.
• W2788085443 cites W2093467790 @default.
• W2788085443 cites W2112024831 @default.
• W2788085443 cites W2113318243 @default.
• W2788085443 cites W2114313173 @default.
• W2788085443 cites W2118320927 @default.
• W2788085443 cites W2147648477 @default.
• W2788085443 cites W2149962856 @default.
• W2788085443 cites W2158822657 @default.
• W2788085443 cites W2213014172 @default.
• W2788085443 cites W2566106089 @default.
• W2788085443 cites W2605692309 @default.
• W2788085443 cites W2725660306 @default.
• W2788085443 cites W294314005 @default.
• W2788085443 doi "https://doi.org/10.1016/j.cgh.2018.02.026" @default.
• W2788085443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29481969" @default.
• W2788085443 hasPublicationYear "2018" @default.
• W2788085443 type Work @default.
• W2788085443 sameAs 2788085443 @default.
• W2788085443 citedByCount "34" @default.
• W2788085443 countsByYear W27880854432018 @default.
• W2788085443 countsByYear W27880854432019 @default.
• W2788085443 countsByYear W27880854432020 @default.
• W2788085443 countsByYear W27880854432021 @default.
• W2788085443 countsByYear W27880854432022 @default.
• W2788085443 countsByYear W27880854432023 @default.
• W2788085443 crossrefType "journal-article" @default.
• W2788085443 hasAuthorship W2788085443A5000862541 @default.
• W2788085443 hasAuthorship W2788085443A5005545298 @default.
• W2788085443 hasAuthorship W2788085443A5009183382 @default.
• W2788085443 hasAuthorship W2788085443A5012036209 @default.
• W2788085443 hasAuthorship W2788085443A5019673979 @default.
• W2788085443 hasAuthorship W2788085443A5027039445 @default.
• W2788085443 hasAuthorship W2788085443A5032323138 @default.
• W2788085443 hasAuthorship W2788085443A5032847603 @default.
• W2788085443 hasAuthorship W2788085443A5034266154 @default.
• W2788085443 hasAuthorship W2788085443A5044736668 @default.
• W2788085443 hasAuthorship W2788085443A5044808426 @default.
• W2788085443 hasAuthorship W2788085443A5055011014 @default.
• W2788085443 hasAuthorship W2788085443A5055703254 @default.
• W2788085443 hasAuthorship W2788085443A5065695520 @default.
• W2788085443 hasAuthorship W2788085443A5065914205 @default.
• W2788085443 hasAuthorship W2788085443A5066903532 @default.
• W2788085443 hasAuthorship W2788085443A5067749370 @default.
• W2788085443 hasAuthorship W2788085443A5069787247 @default.
• W2788085443 hasAuthorship W2788085443A5070743956 @default.
• W2788085443 hasAuthorship W2788085443A5074626064 @default.
• W2788085443 hasAuthorship W2788085443A5075701151 @default.
• W2788085443 hasAuthorship W2788085443A5080357947 @default.
• W2788085443 hasAuthorship W2788085443A5083810588 @default.
• W2788085443 hasAuthorship W2788085443A5087970044 @default.
• W2788085443 hasAuthorship W2788085443A5089064008 @default.
• W2788085443 hasConcept C126322002 @default.
• W2788085443 hasConcept C139059822 @default.
• W2788085443 hasConcept C141071460 @default.
• W2788085443 hasConcept C168563851 @default.
• W2788085443 hasConcept C2780221984 @default.
• W2788085443 hasConcept C511355011 @default.
• W2788085443 hasConcept C544821477 @default.
• W2788085443 hasConcept C71924100 @default.
• W2788085443 hasConceptScore W2788085443C126322002 @default.

• next